Stay updated with breaking news from Immunization Practices. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
One of the big headlines from a major scientific meeting recently: The HPV vaccine not only prevents cervical cancer but reduces the risk of multiple other cancers and even pre-malignant lesions.
HPV has also been linked to head and neck cancers in men. The researchers who did the study found that the vaccine can reduce the risk of getting these cancers by 50%.
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.
The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.
'Even with some variation, there's still reasonably good protection'